Colorized structure of a prototype for a universal flu vaccine. The nanoparticle is a hybrid of a protein scaffold (blue) and eight influenza hemagglutinin proteins on the surface (yellow). The hemagglutinin was specifically engineered to display antibody binding sites common to all human influenza subtypes. The particle designed by Jeffrey Boyington (VRC) has been shown to be an effective immunogen in mice and ferrets (VRC). 3D structure of the particle was determined by cryo-electron microscopy by John Gallagher and Audray Harris (Laboratory of Infectious Diseases).
Credit
NIAID
Influenza Research at NIAID
NIAID is conducting and supporting research to find new and improved ways to diagnose, treat and prevent influenza infection.
Intramural Scientist & Clinician Directory
Search a listing of NIAID scientists and clinicians including principal investigators (PIs), staff scientists and staff clinicians.
Colorized transmission electron micrograph of monkeypox virus particles (green) cultivated and purified from cell culture. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland
Credit
NIAID
NIAID Monkeypox Research Role
NIAID played a key role in the available preventive monkeypox vaccine as well as treatments that may be used. NIAID continues to conduct research to better understand monkeypox transmission and disease.
